These are interesting findings that the commercially available 21-gene expression assay has been only validated to quantify the risk of distant disease recurrence in those diagnosed with ER+/HER2− breast cancer, by successfully selecting those with tumors of more aggressive biology to receive combined chemoendocrine therapy. The gene discussed is ESR1; the disease is breast cancer.